Gadoxetic acid in China: a narrative review of the 15-year journey and the road ahead.
10 affiliations
- 1Department of Medical Imaging Center, Nanfang Hospital, Southern Medical University, Guangzhou, China.
- 2Department of Radiology, Guangzhou First People's Hospital, Guangzhou, China.
- 3Department of Radiology, Mayo Clinic, Rochester, MN, USA.
- 4School of Mathematics and Statistics, University of New South Wales, New South Wales, Australia.
- 5Department of Radiology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China.
- 6Department of Radiology, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
- 7Department of Imaging and Interventional Radiology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China.
- 8Berlin Ultrahigh Field Facility (B.U.F.F.), Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
- 9Guangdong Provincial Key Laboratory of Artificial Intelligence in Medical Image Analysis and Application, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
- 10Department of Radiology, The Third Affiliated Hospital of Southern Medical University, Southern Medical University, Guangzhou, China.
Abstract
Since its pivotal introduction in 2011, gadoxetic acid has fundamentally revolutionized the landscape of hepatobiliary imaging in China, shifting the diagnostic paradigm from morphological assessment toward functional hepatocyte-level evaluation. This review comprehensively summarizes its 15-year clinical evolution within the Chinese healthcare system, exploring its pharmacological benefits, advanced applications, and future integration with data-driven frameworks. A systematic literature search was conducted across major electronic databases, including PubMed, Web of Science, and China National Knowledge Infrastructure, spanning from 2011 to 2026. The search targeted peer-reviewed articles, consensus statements, clinical guidelines, and high-impact reviews published in English and Chinese regarding gadoxetic acid-enhanced liver magnetic resonance imaging (MRI). Gadoxetic acid provides high sensitivity for early small hepatocellular carcinoma (sHCC) detection via specific OATP1B3 uptake. Beyond lesion detection, its quantitative mapping shows potential for estimating hepatic functional reserve (HFR) and risk stratification for post-hepatectomy liver failure. Crucially, the ongoing paradigm shift toward integrating radiomics and deep learning bridges macroscopic imaging and microscopic molecular biology, theoretically enabling a multi-dimensional profile of liver parenchyma and lesions within a single diagnostic session. However, a significant gap remains between retrospective predictive performance and clinical readiness, and these data-driven frameworks currently serve as supplementary investigational engines rather than standalone clinical decision-makers. Moving forward, integrating these high-dimensional signatures into constructs such as "digital twin" represents the next frontier. Furthermore, China's hepatitis B virus-dominant epidemiological cohorts, comprehensive multi-modal datasets, "Med-Engineering" fusion, and collaborative networks uniquely accelerate the development and preliminary validation of these models, offering valuable insights for global precision hepatology within China's healthcare system. Over the past 15 years, gadoxetic acid has evolved far beyond a conventional liver imaging tool in China. While clinical translation of advanced analytics requires rigorous, prospective multicenter validation to ensure safety, combining this functional imaging agent with data-driven frameworks represents a promising frontier to eventually optimize future radiology workflows and support personalized precision hepatology.
Related
- Real-world patient journey and unmet needs of people with hidradenitis suppurativa: Social media research in China.
- A narrative review of the decade-long integration of professional postgraduate education with standardized residency training in China
- Barriers, facilitators, and prioritised service-improvement suggestions across the breast and cervical cancer screening journey: a two-phase exploratory study in rural multi-ethnic northwestern China
- Epilepsy in Tibetan-Inhabited Plateau Regions of Western China: A Narrative Review of Epidemiology, Uncertainty About Chronic High-Altitude Effects, and Evidence-Informed Healthcare Priorities.
- Influencing Factors of Medical Narrative Competence Among Clinical Nurses in China: A Systematic Review and Meta‐Analysis
BibTeX
@article{liu2026gadoxetic,
title = {{Gadoxetic acid in China: a narrative review of the 15-year journey and the road ahead.}},
author = {Yan Liu and Xin Chen and Yiming Wang and Jianming Dong and Lifen Yan and Xiangtian Zhao and Guangyi Wang and Changhong Liang and Cheng Lu and Jifei Wang and Shiting Feng and Yì Xiáng J Wáng and Thoralf Niendorf and Zaiyi Liu and Kaixuan Zhao},
journal = {Quantitative imaging in medicine and surgery},
year = {2026},
month = sep,
doi = {10.21037/qims-2026-1127},
url = {https://europepmc.org/article/MED/42999357},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Gadoxetic acid in China: a narrative review of the 15-year journey and the road ahead.
AU - Yan Liu
AU - Xin Chen
AU - Yiming Wang
AU - Jianming Dong
AU - Lifen Yan
AU - Xiangtian Zhao
AU - Guangyi Wang
AU - Changhong Liang
AU - Cheng Lu
AU - Jifei Wang
AU - Shiting Feng
AU - Yì Xiáng J Wáng
AU - Thoralf Niendorf
AU - Zaiyi Liu
AU - Kaixuan Zhao
PY - 2026
DA - 2026/09/30
JO - Quantitative imaging in medicine and surgery
DO - 10.21037/qims-2026-1127
UR - https://europepmc.org/article/MED/42999357
AB - Since its pivotal introduction in 2011, gadoxetic acid has fundamentally revolutionized the landscape of hepatobiliary imaging in China, shifting the diagnostic paradigm from morphological assessment toward functional hepatocyte-level evaluation. This review comprehensively summarizes its 15-year clinical evolution within the Chinese healthcare system, exploring its pharmacological benefits, advanced applications, and future integration with data-driven frameworks. A systematic literature search was conducted across major electronic databases, including PubMed, Web of Science, and China National Knowledge Infrastructure, spanning from 2011 to 2026. The search targeted peer-reviewed articles, consensus statements, clinical guidelines, and high-impact reviews published in English and Chinese regarding gadoxetic acid-enhanced liver magnetic resonance imaging (MRI). Gadoxetic acid provides high sensitivity for early small hepatocellular carcinoma (sHCC) detection via specific OATP1B3 uptake. Beyond lesion detection, its quantitative mapping shows potential for estimating hepatic functional reserve (HFR) and risk stratification for post-hepatectomy liver failure. Crucially, the ongoing paradigm shift toward integrating radiomics and deep learning bridges macroscopic imaging and microscopic molecular biology, theoretically enabling a multi-dimensional profile of liver parenchyma and lesions within a single diagnostic session. However, a significant gap remains between retrospective predictive performance and clinical readiness, and these data-driven frameworks currently serve as supplementary investigational engines rather than standalone clinical decision-makers. Moving forward, integrating these high-dimensional signatures into constructs such as "digital twin" represents the next frontier. Furthermore, China's hepatitis B virus-dominant epidemiological cohorts, comprehensive multi-modal datasets, "Med-Engineering" fusion, and collaborative networks uniquely accelerate the development and preliminary validation of these models, offering valuable insights for global precision hepatology within China's healthcare system. Over the past 15 years, gadoxetic acid has evolved far beyond a conventional liver imaging tool in China. While clinical translation of advanced analytics requires rigorous, prospective multicenter validation to ensure safety, combining this functional imaging agent with data-driven frameworks represents a promising frontier to eventually optimize future radiology workflows and support personalized precision hepatology.
SN - 2223-4292
SN - 2223-4306
ER -